ICIs, especially agents targeting the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), provide robust benefits for patients with advanced melanoma (5). This evidence concerns the gene CD274 and melanoma.